09:54 AM EST - HLS Therapeutics Inc. : Announced its financial results for the year ended December 31, 2019. Revenue was $54.2 million compared to $61.4 million in 2018. Adjusted EBITDA was $31.6 million compared to $41.1 million in 2018. Net loss was ($19.6) million, or ($0.67) per common share, compared to net loss of ($24.8) million, or ($0.92) per common share, in 2018. HLS Therapeutics Inc.
shares T.HLS are trading unchanged at $15.25.
